United States Drug Patent 8,926,953: Claim Scope, Exclusivity, Litigation Risk, and Bimatoprost Patent Landscape

US Patent 8,926,953 covers topical use of bimatoprost to enhance the growth of eyelashes, eyebrows, or scalp hair. Its principal commercial target is once-daily application of a 0.03% bimatoprost solution to the upper eyelid margin for eyelash hypotrichosis. The patent claims methods of treatment rather than a specific branded product or a standalone bimatoprost composition.

The broadest independent claims are method claims 1 and 10. The patent does not require a particular brand, manufacturer, preservative, applicator, package, or indication wording. A competing product can face infringement risk if it is marketed, prescribed, labeled, or promoted for the claimed hair-growth uses, even if it uses a different formulation platform.

What does US Patent 8,926,953 cover?

US 8,926,953 covers topical administration of a composition containing bimatoprost to promote growth of eyelashes, eyebrows, or scalp hair. The patent claims are organized around four technical elements:

The active ingredient is bimatoprost.
The product is applied topically.
The purpose is enhancement of hair growth.
The target is eyelashes, eyebrows, or scalp hair.

The strongest commercial embodiment is a 0.03% weight/volume bimatoprost solution applied once daily to the upper eyelid margin for eyelash hypotrichosis.

The claims do not require that the patient have a particular severity of hypotrichosis except where the dependent claims expressly recite that condition. The claims also do not require a specific vehicle, preservative system, container, brush, or applicator.

How many independent claims does US 8,926,953 have?

The issued claim set contains two independent claims:

Claim	Independent claim scope	Main limitation
1	Method of enhancing growth of eyelashes, eyebrows, or scalp hair	Topical application of a bimatoprost composition
10	Method of enhancing growth of eyelashes, eyebrows, or scalp hair	Topical application at least once daily of a bimatoprost-containing composition

Claim 1 is broader as to dosing frequency because it does not expressly require application at least once per day. Claim 10 adds the frequency limitation but provides broader formulation alternatives through its dependents.

Claims 2-9 depend from claim 1. Claims 11-20 depend from claim 10. Claims 21-26 narrow the claimed eyelash attributes.

What do claims 1 and 10 require?

Claim 1

Claim 1 requires:

A method of enhancing growth;
Of eyelashes, eyebrows, or scalp hair;
By topical application;
Of a composition containing bimatoprost.

The claim is not limited to eyelash hypotrichosis. Eyelash growth enhancement, eyebrow growth enhancement, and scalp-hair growth enhancement are all expressly included.

The claim does not specify:

Bimatoprost concentration;
Application frequency;
Dosage volume;
Formulation type;
Treatment duration;
Particular patient population;
A requirement that the hair-growth effect be clinically measurable.

A product used for a covered purpose could fall within claim 1 even if it is supplied as a cream, gel, foam, emulsion, or other topical vehicle.

Claim 10

Claim 10 requires the same general therapeutic purpose but adds application "at least once a day." The claim is therefore narrower in frequency but remains broad regarding formulation and concentration.

A once-daily bimatoprost product marketed for eyelash, eyebrow, or scalp-hair growth would be the most direct target of claim 10.

What formulations are protected by US 8,926,953?

The patent claims bimatoprost in multiple dosage forms and concentration ranges.

Claim	Formulation or concentration limitation
2	Bimatoprost solution
3	0.03% w/v bimatoprost solution
11	0.001%-50% w/v bimatoprost
12	0.03% w/v bimatoprost
13	0.1%-30% w/v bimatoprost
19	Emulsion
20	Solution, emulsion, foam, gel, or cream

The concentration claims overlap. A 0.03% w/v solution falls within claim 11's broad range and is separately protected by claims 12, 14, 15, and 16 when the other stated limitations are met.

The claims are not limited to a solution. A bimatoprost emulsion, foam, gel, or cream can fall within claim 20 if it is applied at least once daily for the claimed hair-growth purpose.

Scope of the 0.03% claims

The 0.03% claims create the most direct overlap with Latisse's approved strength. Claims 3 and 12 cover the concentration generally. Claims 14-16 narrow the use to eyelash hypotrichosis or eyelash enhancement and, in claim 16, once-daily application to the upper eyelid margin.

A formulation using a concentration outside 0.03% is not automatically outside the patent. Claims 11 and 13 cover broad concentration ranges. A lower- or higher-concentration product may still be captured if the concentration falls within one of those ranges and the method satisfies the remaining limitations.

What hair-growth outcomes are protected?

Claims 6-8 and 21-26 cover increases in eyelash length, thickness, or darkness.

Claim group	Protected outcome
Claims 6 and 24	Increased length
Claims 6 and 25	Increased thickness
Claims 6 and 26	Increased darkness
Claim 7	At least two of length, thickness, and darkness
Claim 8	All three attributes
Claims 21-23	Length, thickness, or darkness in the claim 14 pathway

The patent uses alternative claiming. A product need not increase all three attributes to face risk. An alleged increase in only eyelash length can satisfy the narrower length claims if the remaining limitations are present.

The specification and prosecution history would control how "enhancing growth" and the listed attributes are construed in litigation. The claim language does not expressly require a particular numerical increase or a fixed evaluation period.

Does the patent cover eyelash, eyebrow, and scalp-hair products?

Yes. The claims expressly identify all three target sites.

Eyelashes

Eyelash growth is the commercially important embodiment. Claims 4-8 and 14-16 specifically narrow the patent toward eyelash enhancement and hypotrichosis treatment.

Claim 16 is particularly relevant to Latisse-type products because it requires:

0.03% w/v bimatoprost solution;
Once-daily application;
Application to the upper eyelid margin.

Eyebrows

Claims 1, 9, 10, 17, and 18 cover eyebrow-related uses when the composition is applied directly to the skin beneath the eyebrows. A product promoted specifically for eyebrow growth may present method-of-use risk even if it is not approved for that indication.

Scalp hair

Claims 1, 9, 10, and 17 cover direct application to the scalp. A bimatoprost scalp-hair product would need to address both patent risk and regulatory requirements for a new indication.

What is the patent's legal scope?

US 8,926,953 is a use patent. It does not, on its face, claim:

The bimatoprost molecule itself;
A specific manufacturing process;
A particular bottle or applicator;
A proprietary preservative;
A fixed commercial package;
A diagnostic method.

Its enforcement theory would generally focus on use of bimatoprost for the claimed hair-growth purpose.

Direct infringement is most naturally associated with the person or entity practicing the method. Commercial exposure can also arise through induced infringement allegations against a manufacturer, distributor, telehealth provider, pharmacy, or marketing company that actively encourages the claimed use. Labeling, promotional materials, dosing instructions, and provider communications would be important evidence.

A product labeled solely for an unrelated ophthalmic indication presents a different analysis. Under US patent law, an ANDA applicant can reduce risk by using a permissible section viii "skinny label" that omits a patented indication. That strategy does not eliminate risk if the applicant or downstream parties actively encourage the patented use. The Federal Circuit's decisions in Warner-Lambert v. Apotex and GlaxoSmithKline v. Teva illustrate the importance of label content and inducement evidence. [4, 5]

When does US Patent 8,926,953 lose exclusivity?

The patent was issued on January 6, 2015. Public patent records identify a February 27, 2009 priority date for the relevant family. On that basis, the nominal 20-year patent term runs to approximately February 27, 2029, subject to any patent-term adjustment, terminal disclaimer, disclaimer filing, or other USPTO-recorded term event. [1, 2]

Event	Date
Earliest reported priority	February 27, 2009
Patent issuance	January 6, 2015
Nominal term endpoint	Approximately February 27, 2029
Commercial exclusivity after expiration	Subject to other patents, regulatory status, and litigation

The patent's expiration must be distinguished from FDA regulatory exclusivity. Patent expiration does not itself establish that an ANDA applicant can immediately market a product. A later-filed patent, a listed patent for another product, an injunction, or regulatory requirements may affect launch timing.

What is the FDA and Orange Book status of the bimatoprost products?

Latisse, a 0.03% bimatoprost ophthalmic solution, received FDA approval under NDA 022369 in December 2008 for hypotrichosis of the eyelashes. The approved labeling describes once-daily application to the upper eyelid margins and identifies increased eyelash length, thickness, and darkness as treatment effects. [3]

Lumigan, another bimatoprost product, was approved under NDA 020597 for reduction of elevated intraocular pressure in glaucoma or ocular hypertension. Its approved ophthalmic indication is different from Latisse's eyelash-hypotrichosis indication. [6]

Product	Active ingredient	FDA pathway	Primary indication
Latisse	Bimatoprost 0.03%	NDA 022369	Eyelash hypotrichosis
Lumigan	Bimatoprost ophthalmic solution	NDA 020597	Glaucoma and ocular hypertension
Generic bimatoprost ophthalmic products	Bimatoprost	ANDA pathway	Ophthalmic pressure reduction, depending on product

FDA approval of generic bimatoprost ophthalmic products does not automatically authorize eyelash-growth marketing. The indication, labeling, formulation, and Orange Book listings must be assessed product by product.

FDA-listed patents for an NDA are not identical to every patent that may be asserted in commercial litigation. The Orange Book is central to Hatch-Waxman patent certification, but it does not replace a complete USPTO and litigation search. [7]

What other patents are relevant to the bimatoprost landscape?

The relevant estate includes three principal categories.

Bimatoprost composition and ophthalmic-use patents

Earlier Allergan patents cover bimatoprost ophthalmic compositions and glaucoma-related uses. US Patent 6,262,105 is an important early bimatoprost patent and relates to ophthalmic use and compositions. Its term has ended under the ordinary US patent-term framework. [8]

These patents are technically relevant but generally do not provide the same current hair-growth protection as US 8,926,953.

Eyelash-growth patents

US Patent 7,351,404 is associated with methods of enhancing eyelash growth and is one of the principal historical patents connected to the Latisse product. Its term is materially earlier than that of US 8,926,953 and has been a central consideration in generic and post-expiration planning. [9]

The two patents should not be treated as interchangeable. US 7,351,404 and US 8,926,953 may differ in claim wording, priority chain, expiration, prosecution history, and Orange Book treatment. A freedom-to-operate opinion must map each proposed product and indication against both estates.

Formulation and manufacturing patents

Bimatoprost products can also encounter patents directed to:

Preservative systems;
pH and osmolarity;
Solubilization;
Container closure systems;
Sterile ophthalmic manufacturing;
Applicators and dosing devices;
Stabilization and packaging.

A noninfringing concentration or indication does not resolve risk from a separate formulation or manufacturing patent.

Which companies are most exposed to this patent?

The principal exposure groups are:

Company type	Risk profile
Branded eyelash-growth sponsor	High, if using bimatoprost at or near 0.03%
Generic ophthalmic manufacturer	Moderate for approval; higher if labeling or promotion includes eyelash growth
Cosmetic lash-growth company	High if the product contains bimatoprost and makes growth claims
Telehealth provider	High inducement risk where prescribing protocols promote the claimed use
Compounding pharmacy	Product and inducement risk depends on formulation and promotional conduct
Scalp-hair developer	High method-of-use risk, although clinical and regulatory development is separate

Companies selling cosmetic products without bimatoprost face a lower risk under this patent, although other patents, trademark rights, FDA claims-substantiation rules, and state consumer-protection law remain relevant.

What Paragraph IV and generic-launch risks exist?

A generic applicant seeking approval for an eyelash-hypotrichosis product would likely confront the listed-patent and labeling consequences associated with the Latisse NDA. Potential pathways include:

Paragraph III certification, deferring launch until patent expiration;
Paragraph IV certification, challenging validity, enforceability, or infringement;
Section viii statement, omitting a patented indication where legally available;
A separate NDA or 505(b)(2) application for a changed formulation or indication.

A Paragraph IV notice can trigger Hatch-Waxman litigation and a statutory 30-month stay of approval under the conditions specified in the Food, Drug, and Cosmetic Act. [10] The commercial value of a challenge depends on whether the applicant seeks the eyelash indication or only an ophthalmic-pressure indication.

A skinny-label strategy is more viable for a generic glaucoma product than for a product expressly marketed for eyelash enhancement. Promotional materials, provider education, website content, and patient instructions can undermine the separation between the approved noninfringing indication and the patented use.

How strong is the patent estate for Latisse-type products?

The estate is strongest against a product that combines all of the following:

Bimatoprost;
0.03% w/v concentration;
Topical application;
Once-daily dosing;
Upper-eyelid-margin application;
Eyelash hypotrichosis treatment;
Claims of increased length, thickness, or darkness.

Risk is lower, but not necessarily eliminated, for:

A different concentration within claims 11 or 13;
A cream, gel, foam, or emulsion;
Eyebrow or scalp use;
A non-daily dosing schedule under claim 1;
A product that omits hair-growth marketing but is used off label.

The patent has meaningful breadth because the independent claims are not limited to Latisse's exact commercial formulation. Its main limitation is legal: it is a method patent, so infringement depends heavily on intended use, instructions, promotion, and actual conduct.

What licensing and settlement issues affect the landscape?

Publicly documented licensing and settlement terms should be reviewed through SEC filings, ANDA litigation dockets, and FDA patent records. The supplied claim set does not establish a license, covenant not to sue, settlement, or authorized generic arrangement.

For transaction diligence, the relevant documents include:

Patent assignment records;
Allergan or AbbVie licensing disclosures;
ANDA Paragraph IV notices;
District court complaints and judgments;
Consent judgments and settlement agreements;
Authorized-generic or supply agreements;
Orange Book patent listings and delistings.

A settlement may control launch timing without changing the patent's statutory expiration. Confidential commercial terms may also affect market entry even when the public docket provides only a dismissal or agreed judgment.

Key Takeaways

US 8,926,953 claims topical bimatoprost use for eyelash, eyebrow, and scalp-hair growth.
Claims 1 and 10 are the two independent method claims.
The most commercially important embodiment is 0.03% bimatoprost solution applied once daily to the upper eyelid margin.
The patent covers solutions, emulsions, foams, gels, and creams through its dependent claims.
Claims cover increased eyelash length, thickness, darkness, or combinations of those attributes.
The patent's nominal term is approximately February 27, 2029, subject to the official USPTO term calculation.
Generic bimatoprost approval for glaucoma does not itself authorize eyelash-growth marketing.
Paragraph IV, section viii, labeling, inducement, and downstream promotion are central launch-risk issues.
Earlier bimatoprost and eyelash-growth patents form part of the broader estate and require separate claim-by-claim analysis.
Formulation, packaging, manufacturing, and applicator patents may create additional barriers beyond US 8,926,953.

FAQs

Does US 8,926,953 claim Latisse itself?

No. It primarily claims methods of using bimatoprost for hair-growth enhancement. The claims do not expressly require the Latisse brand, a specific manufacturer, or the complete Latisse commercial package.

Can a non-0.03% bimatoprost product avoid the patent?

Not necessarily. Claims 11 and 13 cover broad concentration ranges. A product outside 0.03% may still fall within those claims if it is topically applied at least once daily for the claimed hair-growth purpose.

Does a bimatoprost cosmetic product infringe if it does not say "hypotrichosis"?

Potentially. Claims 1 and 10 do not require the word "hypotrichosis." Marketing or use directed to enhancing eyelash, eyebrow, or scalp-hair growth can satisfy the claimed purpose.

Are bimatoprost biosimilars relevant to US 8,926,953?

No. Bimatoprost is a small-molecule drug, not a biologic. The relevant competitive pathways are ANDAs, 505(b)(2) applications, NDAs, compounded products, and cosmetic products, rather than biosimilar applications.

Can a company avoid infringement by changing the delivery vehicle?

Changing from a solution to a gel, foam, cream, or emulsion may not avoid infringement because claim 20 expressly includes those dosage forms. The proposed product must be analyzed against every asserted claim, not only the solution claims.

References

United States Patent and Trademark Office. (2015). US Patent No. 8,926,953, Methods of enhancing hair growth.
Google Patents. (n.d.). US8926953B2: Methods of enhancing hair growth. https://patents.google.com/patent/US8926953B2/en
U.S. Food and Drug Administration. (2008). Latisse, NDA 022369, prescribing information.
Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348 (Fed. Cir. 2003).
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021).
U.S. Food and Drug Administration. (2001). Lumigan, NDA 020597, prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
United States Patent and Trademark Office. (2001). US Patent No. 6,262,105.
United States Patent and Trademark Office. (2008). US Patent No. 7,351,404, Methods of enhancing eyelash growth.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003207843	⤷ Start Trial
Australia	2008203212	⤷ Start Trial
Australia	2010227111	⤷ Start Trial
Australia	2012261499	⤷ Start Trial
Australia	2013208002	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,926,953

Summary for Patent: 8,926,953